• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

Professional Introduction to Compound with CAS No. 486437-66-5 and Product Name: 1-[4-(3-methylpiperidin-1-yl)phenyl]methanamine

The compound with the CAS number 486437-66-5 and the product name 1-[4-(3-methylpiperidin-1-yl)phenyl]methanamine represents a significant advancement in the field of pharmaceutical chemistry. This compound belongs to a class of molecules that have garnered considerable attention due to their potential applications in drug discovery and development. The structural framework of this molecule, featuring a benzylamine moiety linked to a 3-methylpiperidine ring, suggests a high degree of specificity that could be exploited for therapeutic purposes.

Recent research in medicinal chemistry has highlighted the importance of piperidine derivatives in the design of novel bioactive compounds. The presence of the 3-methylpiperidine substituent in this molecule not only contributes to its unique pharmacophore but also enhances its solubility and metabolic stability, which are critical factors for drug-like properties. The benzylamine group, on the other hand, provides a versatile handle for further chemical modifications, enabling the synthesis of more complex derivatives with tailored biological activities.

One of the most compelling aspects of this compound is its potential role as an intermediate in the synthesis of more sophisticated pharmaceutical agents. The combination of the 4-(3-methylpiperidin-1-yl)phenyl scaffold with the methanamine backbone creates a platform that can be readily functionalized to target specific biological pathways. For instance, studies have shown that similar structures can interact with enzymes and receptors involved in inflammation, pain management, and neurodegenerative diseases. This makes 1-[4-(3-methylpiperidin-1-yl)phenyl]methanamine a promising candidate for further investigation in these therapeutic areas.

The pharmacological profile of this compound is further supported by computational modeling studies, which have predicted favorable binding affinities to various target proteins. These simulations have been instrumental in guiding experimental efforts and optimizing the compound's structure for improved efficacy and selectivity. The integration of computational chemistry with traditional synthetic methodologies has significantly accelerated the drug discovery process, making compounds like 1-[4-(3-methylpiperidin-1-yl)phenyl]methanamine more accessible for preclinical testing.

In addition to its structural merits, this compound exhibits interesting physicochemical properties that make it an attractive candidate for pharmaceutical development. Its molecular weight and lipophilicity profile are within optimal ranges for oral bioavailability, while its solubility characteristics enhance its suitability for formulation into various dosage forms. These attributes are particularly important in the context of developing new treatments for chronic conditions where patient compliance is crucial.

Recent advances in analytical techniques have also contributed to a deeper understanding of this compound's behavior in biological systems. Techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and X-ray crystallography have provided valuable insights into its conformational dynamics and interactions with biological targets. These data are essential for refining structure-activity relationships (SAR) and guiding the design of next-generation derivatives.

The synthesis of 1-[4-(3-methylpiperidin-1-yl)phenyl]methanamine involves multi-step organic reactions that showcase the ingenuity of modern synthetic chemistry. Key steps include palladium-catalyzed cross-coupling reactions to construct the aromatic core, followed by nucleophilic substitution to introduce the piperidine moiety. These reactions highlight the importance of transition metal catalysis in facilitating complex bond formations under mild conditions. The optimization of these synthetic routes has been crucial in ensuring high yields and purity, which are essential for subsequent pharmacological evaluation.

The potential therapeutic applications of this compound are vast and span multiple disease areas. For example, its structural similarity to known antihistamines suggests that it may exhibit anti-allergic properties, while its interaction with central nervous system (CNS) receptors points towards potential uses in treating cognitive disorders. Additionally, preliminary data suggest that it may possess anti-inflammatory effects, making it relevant for conditions such as rheumatoid arthritis or inflammatory bowel disease.

Ongoing clinical trials are exploring novel therapeutic agents based on similar chemical scaffolds, providing a strong rationale for investigating compounds like 1-[4-(3-methylpiperidin-1-yl)phenyl]methanamine further. These trials often focus on targeting underserved therapeutic niches or addressing unmet medical needs where current treatments are limited or ineffective. The success of such trials would not only validate the underlying chemistry but also open up new avenues for drug development.

The regulatory landscape surrounding new pharmaceutical entities is increasingly stringent, necessitating rigorous safety and efficacy evaluations before market approval. However, compounds derived from well-characterized scaffolds like 1-[4-(3-methylpiperidin-1-yl)phenyl]methanamine may benefit from accelerated review pathways if they demonstrate significant therapeutic advantages over existing treatments. This underscores the importance of early-stage investment in research and development to bring innovative medicines to patients more quickly.

In conclusion, 1-[4-(3-methylpiperidin-1-yl)phenyl]methanamine (CAS No. 486437-66-5) represents a promising candidate for further exploration in pharmaceutical research. Its unique structural features, combined with favorable physicochemical properties and potential therapeutic applications, make it an attractive molecule for drug discovery efforts. As our understanding of biological systems continues to evolve, compounds like this one will play an increasingly important role in addressing complex diseases and improving patient outcomes worldwide.

• 214759-73-6(1-[4-(piperidin-1-yl)phenyl]methanamine)
• 136423-30-8(Piperidine, 1-phenyl-3-(phenylmethyl)-)
• 486437-83-6
• 852180-55-3(N-methyl-N-(4-piperidin-1-ylbenzyl)amine)
• 486437-62-1
• 923603-44-5(Benzenemethanamine, N-(4-methylphenyl)-N-(2-methylpropyl)-)
• 175696-71-6(3-(1-Piperidyl)benzylamine)
• 852180-56-4(N-(4-Piperidin-1-ylbenzyl)-N-propylamine)
• 869945-54-0({1-4-(3-Methylpiperidin-1-yl)phenylethyl}amine)
• 486437-59-6(1-4-(4-methylpiperidin-1-yl)phenylmethanamine)